CEL-SCI’s Multikine® Granted Saudi FDA NADR Designation, Advancing Commercialization Plans

CEL-SCI’s Multikine Receives Saudi Arabia’s NADR Designation, Advancing Potential First Global Commercial Launch in 2027 CEL-SCI Corporation, a clinical-stage biotechnology company developing investigational immunotherapy treatments for cancer, announced that its…

Read MoreCEL-SCI’s Multikine® Granted Saudi FDA NADR Designation, Advancing Commercialization Plans

United Therapeutics Announces First UThymoKidney™ Transplant in EXTEND Clinical Trial for End-Stage Renal Disease

United Therapeutics Announces First UThymoKidney Xenotransplant in EXTEND Clinical Trial for Patients with End-Stage Renal Disease United Therapeutics Corporation, a public benefit corporation focused on developing innovative therapies and technologies…

Read MoreUnited Therapeutics Announces First UThymoKidney™ Transplant in EXTEND Clinical Trial for End-Stage Renal Disease

Merck Reports TroFuse-015 Trial Met Overall Survival Primary Endpoint for Sacituzumab Tirumotecan in Advanced Gastroesophageal Adenocarcinoma

Merck’s Sacituzumab Tirumotecan Demonstrates Overall Survival Benefit in Phase 3 TroFuse-015 Trial for Advanced Gastroesophageal Cancer Merck, known as MSD outside the United States and Canada, has announced positive results…

Read MoreMerck Reports TroFuse-015 Trial Met Overall Survival Primary Endpoint for Sacituzumab Tirumotecan in Advanced Gastroesophageal Adenocarcinoma

Epitech Group and Horus Pharma Sign Global Licensing Agreement to Advance Adelmidrol Development in Eye Health

Epitech Group and Horus Pharma Sign Global Licensing Agreement to Advance Adelmidrol Development in Ophthalmology Epitech Group S.p.A., an Italian biopharmaceutical company specializing in neuro-inflammation, and Horus Pharma, a French…

Read MoreEpitech Group and Horus Pharma Sign Global Licensing Agreement to Advance Adelmidrol Development in Eye Health

Axoft Highlights Clinical Progress of Its Ultra-Soft Fleuron™ Brain-Computer Interface Probes

Axoft Reports Major Clinical Milestones for Fleuron Brain-Computer Interface, Demonstrating Stable Neural Data Collection and Real-Time Consciousness Decoding Axoft, a neurotechnology company developing advanced brain-computer interface (BCI) technologies, has announced…

Read MoreAxoft Highlights Clinical Progress of Its Ultra-Soft Fleuron™ Brain-Computer Interface Probes